Antoni Sicras-Mainar1, Javier Rejas-Gutiérrez2, Maria Perez-Paramo3, Ruth Navarro-Artieda4. 1. ClinicResearch, Tiana, Barcelona, Spain. 2. Health Economics & Outcomes Research, Pfizer SLU, Alcobendas, Madrid, Spain. 3. Medical Department, Pfizer GEP SLU, Alcobendas, Madrid, Spain. 4. Medical Documentation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Abstract
AIM: To analyze the cost of peripheral neuropathic pain (PNP) treatment with pregabalin or gabapentin at therapeutic doses in routine clinical practice. METHODS: Analysis of a retrospective, observational study of electronic medical records of patients treated for PNP with therapeutic doses of pregabalin or gabapentin, with 2 years' follow-up, considering PNP type, comorbidities, concomitant analgesia and resource use. RESULTS: The weighted total average cost/patient was lower for pregabalin than gabapentin (€2464 [2197-2730] vs €3142 [2670-3614]; p = 0.014) due to significantly lower both healthcare and non-healthcare costs. This is explained by a significantly lower use of concomitant analgesia, fewer primary care visits and fewer days of sick leave. CONCLUSION: At therapeutic doses, pregabalin was found to have lower healthcare and non-healthcare costs than gabapentin in routine practice.
AIM: To analyze the cost of peripheral neuropathic pain (PNP) treatment with pregabalin or gabapentin at therapeutic doses in routine clinical practice. METHODS: Analysis of a retrospective, observational study of electronic medical records of patients treated for PNP with therapeutic doses of pregabalin or gabapentin, with 2 years' follow-up, considering PNP type, comorbidities, concomitant analgesia and resource use. RESULTS: The weighted total average cost/patient was lower for pregabalin than gabapentin (€2464 [2197-2730] vs €3142 [2670-3614]; p = 0.014) due to significantly lower both healthcare and non-healthcare costs. This is explained by a significantly lower use of concomitant analgesia, fewer primary care visits and fewer days of sick leave. CONCLUSION: At therapeutic doses, pregabalin was found to have lower healthcare and non-healthcare costs than gabapentin in routine practice.
Authors: Daniel Bates; B Carsten Schultheis; Michael C Hanes; Suneil M Jolly; Krishnan V Chakravarthy; Timothy R Deer; Robert M Levy; Corey W Hunter Journal: Pain Med Date: 2019-06-01 Impact factor: 3.750
Authors: Manuel E Machado-Duque; Andres Gaviria-Mendoza; Jorge E Machado-Alba; Natalia Castaño Journal: Pain Res Manag Date: 2020-03-30 Impact factor: 3.037
Authors: Cornelius Fernandez James; Shiva Tripathi; Kyriaki Karampatou; Divya V Gladston; Joseph M Pappachan Journal: Sisli Etfal Hastan Tip Bul Date: 2022-03-28